Laurus Labs Limited (BOM: 540222)

Market Cap	315.06B
Revenue (ttm)	50.53B
Net Income (ttm)	1.31B
Shares Out	n/a
EPS (ttm)	2.42
PE Ratio	240.32
Forward PE	n/a
Dividend	0.80 (0.14%)
Ex-Dividend Date	Nov 6, 2024

Volume	72,691
Average Volume	76,234
Open	571.45
Previous Close	568.05
Day's Range	564.05 - 589.60
52-Week Range	358.70 - 619.50
Beta	n/a
RSI	53.24
Earnings Date	Jan 24, 2025

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational ser...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2005
• Employees: 6,007
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540222

Financial Performance

In 2023, Laurus Labs's revenue was 50.41 billion, a decrease of -16.55% compared to the previous year's 60.41 billion. Earnings were 1.61 billion, a decrease of -79.68%.